Hims & Hers Health, Inc. (NYSE:HIMS) CEO Sells $7,272,488.52 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) CEO Andrew Dudum sold 128,127 shares of the business's stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $56.76, for a total transaction of $7,272,488.52. Following the completion of the transaction, the chief executive officer now owns 160,215 shares in the company, valued at $9,093,803.40. The trade was a 44.44% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Andrew Dudum also recently made the following trade(s):

• On Tuesday, June 17th, Andrew Dudum sold 65,110 shares of Hims & Hers Health stock. The shares were sold at an average price of $59.22, for a total transaction of $3,855,814.20.
• On Monday, June 16th, Andrew Dudum sold 47,534 shares of Hims & Hers Health stock. The shares were sold at an average price of $56.51, for a total transaction of $2,686,146.34.
• On Friday, May 16th, Andrew Dudum sold 47,534 shares of Hims & Hers Health stock. The shares were sold at an average price of $58.25, for a total transaction of $2,768,855.50.
• On Friday, May 16th, Andrew Dudum sold 128,127 shares of Hims & Hers Health stock. The shares were sold at an average price of $58.40, for a total transaction of $7,482,616.80.
• On Tuesday, April 29th, Andrew Dudum sold 50,000 shares of Hims & Hers Health stock. The shares were sold at an average price of $36.39, for a total transaction of $1,819,500.00.
• On Wednesday, April 16th, Andrew Dudum sold 36,460 shares of Hims & Hers Health stock. The shares were sold at an average price of $28.04, for a total transaction of $1,022,338.40.

Hims & Hers Health Stock Up 3.1%

Shares of NYSE HIMS traded up $1.85 during midday trading on Wednesday, hitting $61.09. The stock had a trading volume of 43,207,932 shares, compared to its average volume of 21,448,835. The business's 50 day moving average is $47.00 and its 200-day moving average is $38.75. The company has a market cap of $13.67 billion, a P/E ratio of 88.54, a PEG ratio of 2.23 and a beta of 2.09. Hims & Hers Health, Inc. has a 52 week low of $13.47 and a 52 week high of $72.98.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its quarterly earnings data on Monday, May 5th. The company reported $0.20 earnings per share for the quarter, beating analysts' consensus estimates of $0.12 by $0.08. The company had revenue of $586.01 million for the quarter, compared to the consensus estimate of $535.21 million. Hims & Hers Health had a net margin of 9.24% and a return on equity of 22.75%. The firm's revenue for the quarter was up 110.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.05 earnings per share. As a group, analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in HIMS. Raymond James Financial Inc. purchased a new stake in Hims & Hers Health during the fourth quarter valued at approximately $18,048,000. O Shaughnessy Asset Management LLC purchased a new stake in Hims & Hers Health during the fourth quarter valued at approximately $208,000. Commonwealth Equity Services LLC increased its holdings in Hims & Hers Health by 111.6% during the fourth quarter. Commonwealth Equity Services LLC now owns 58,894 shares of the company's stock valued at $1,424,000 after buying an additional 31,062 shares during the last quarter. PNC Financial Services Group Inc. increased its holdings in Hims & Hers Health by 51.9% during the fourth quarter. PNC Financial Services Group Inc. now owns 17,225 shares of the company's stock valued at $417,000 after buying an additional 5,885 shares during the last quarter. Finally, Amundi increased its holdings in Hims & Hers Health by 49.1% during the fourth quarter. Amundi now owns 12,741 shares of the company's stock valued at $328,000 after buying an additional 4,197 shares during the last quarter. Institutional investors own 63.52% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on HIMS. Morgan Stanley reaffirmed an "equal weight" rating and set a $40.00 target price on shares of Hims & Hers Health in a research note on Wednesday, June 11th. Piper Sandler reissued a "neutral" rating and set a $39.00 price objective (up previously from $35.00) on shares of Hims & Hers Health in a research note on Tuesday, May 6th. Canaccord Genuity Group boosted their price objective on shares of Hims & Hers Health from $38.00 to $68.00 and gave the stock a "buy" rating in a research note on Wednesday, February 19th. Bank of America boosted their price objective on shares of Hims & Hers Health from $22.00 to $26.00 and gave the stock an "underperform" rating in a research note on Tuesday, April 29th. Finally, TD Cowen lowered shares of Hims & Hers Health from a "buy" rating to a "hold" rating and dropped their price objective for the stock from $44.00 to $30.00 in a research note on Tuesday, April 29th. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat, Hims & Hers Health currently has a consensus rating of "Hold" and a consensus price target of $38.00.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.